title: Clinical Performance of CEA, CA19-9, CA15-3, CA125 and AFP in Gastrointestinal Cancer Using LOCI™-based Assays.
abstract: Few data are available regarding the clinical performance of LOCI™-based tumor marker assays. We investigated the diagnostic power of carcinogenic antigen, carbohydrate antigen 19-9, carbohydrate antigen 15-3, carbohydrate antigen 125 and alpha-fetoprotein for detection of gastrointestinal (GI) cancer.
  
  
  
  We analyzed sera from 204 patients (107 with GI cancer, 73 with benign GI diseases and 24 healthy controls) using the Dimension™ Vista1500 analyzer.
  
  
  
  Levels of biomarkers in healthy controls were in the expected ranges and were only slightly higher in benign GI controls. Established tumor-type-associated markers were elevated in specific cancer types and discriminated well between cancer and benign controls. Best performance was found for CEA in colorectal cancer (area under the curve=0.84, sensitivity=51.7% at 95% specificity vs. benign), CA19-9 in gallbladder/pancreatic cancer (AUC=0.85, sensitivity=60.6%) and AFP in liver cancer (AUC=0.87, sensitivity=68.4%).
  
  
  
  Our study demonstrated the high diagnostic power of well-known biomarkers. LOCI™-based tumor marker assays give reliable results in routine diagnostics.
authors.affiliation: Department of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
authors.forename: Ramona C
authors.initials: RC
authors.lastname: Dolscheid-Pommerich
authors.affiliation: Department of Surgery, University Hospital Bonn, Bonn, Germany.|Center for Integrated Oncology (CIO), Köln/Bonn, Germany.
authors.forename: Steffen
authors.initials: S
authors.lastname: Manekeller
authors.affiliation: Department of Surgery, University Hospital Bonn, Bonn, Germany.|Center for Integrated Oncology (CIO), Köln/Bonn, Germany.
authors.forename: Gisela
authors.initials: G
authors.lastname: Walgenbach-Brünagel
authors.affiliation: Department of Surgery, University Hospital Bonn, Bonn, Germany.|Center for Integrated Oncology (CIO), Köln/Bonn, Germany.
authors.forename: Jörg C
authors.initials: JC
authors.lastname: Kalff
authors.affiliation: Department of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.|Center for Integrated Oncology (CIO), Köln/Bonn, Germany.
authors.forename: Gunther
authors.initials: G
authors.lastname: Hartmann
authors.affiliation: Department of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
authors.forename: Birgit Stoffel
authors.initials: BS
authors.lastname: Wagner
authors.affiliation: Department of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany stefan.holdenrieder@uni-bonn.de.|Center for Integrated Oncology (CIO), Köln/Bonn, Germany.
authors.forename: Stefan
authors.initials: S
authors.lastname: Holdenrieder
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001681:Biological Assay; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood; D018395:CA-19-9 Antigen / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000097:blood; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000097:blood* / Q000175:diagnosis; D006801:Humans; D008875:Middle Aged; D018396:Mucin-1 / Q000097:blood; D055815:Young Adult; D000509:alpha-Fetoproteins / Q000032:analysis
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; D018396:Mucin-1; D000509:alpha-Fetoproteins
keywords: AFP; CA19-9; CEA; Gastrointestinal cancer; LOCI™-based assay; tumor marker